Celldex Therapeutics Q1 EPS $(0.56) Beats $(0.69) Estimate, Sales $156.00K Miss $920.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Celldex Therapeutics (NASDAQ:CLDX) reported Q1 earnings with a loss of $(0.56) per share, surpassing the expected $(0.69) loss, marking an 18.84% beat. However, their sales of $156.00K fell short of the $920.00K estimate, an 83.04% miss, and represented an 83.87% decrease from the previous year's $967.00K.
May 06, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Celldex Therapeutics reported better-than-expected Q1 EPS but significantly missed sales estimates, with a substantial year-over-year decrease.
The positive EPS beat might provide some upward momentum for CLDX stock, but the significant miss on sales estimates and the sharp decline from the previous year's sales could counteract any positive sentiment. The mixed results create uncertainty about the stock's short-term direction.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100